Upadacitinib Meets Primary Endpoint in JAKPPPOT PPP Trial
Upadacitinib met its primary endpoint in the JAKPPPOT trial for palmoplantar pustulosis, per Medscape. The oral selective JAK1 inhibitor, already approved across rheumatology, gastroenterology and at…